Business
Cellceutix Corporation to Present at Upcoming Conferences
Cellceutix Corporation to Present at Upcoming Conferences.
About this update from Innovation Pharmaceuticals Inc.
[{"type":"text","content":"\nCellceutix Corporation to Present at Upcoming Conferences\n\nCellceutix Corporation to Present at Upcoming Conferences\n\nBEVERLY, MA--(Marketwired - September 07, 2016) - Cellceutix Corporation (OTC: CTIX) (\"the Company\"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications, today announces that management will present at two upcoming conferences highlighting the continuing advancement of the Company's clinical programs.Friday, September 9, 2016 - Cellceutix will present at the 23rd Annual Newsmakers in the Biotech Industry Conference in New York City at 8:30 am ET. This presentation will be made available in the Investors section of the cellceutix.com website.Monday, September 19, 2016 - Cellceutix will present, and participate in multiple panel discussions, at the 14th Annual Discovery on Target Conference in Boston. The Company's main presentation is titled, \"Prurisol: A New Small Molecule under investigation for the treatment of Psoriasis\", and will be made available in the Investors section of the cellceutix.com website. Alerts:Sign-up for Cellceutix email alerts is available athttp://cellceutix.com/email-alerts/ - sthash.CRfqSmmY.k6MzKBo8.dpbsAbout Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol \"CTIX\". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its plans for a Phase 2 study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the \"Guardian Angel Gene\" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% com...